Trials / Terminated
TerminatedNCT03929822
Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis
Contrast-Enhanced Spectral Mammography: Potential to Improve Diagnostic Accuracy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 32 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether contrast-enhanced spectral mammography (CESM) may be able to reduce the number of unnecessary biopsies in women whose screening mammograms had abnormal findings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Contrast-Enhanced Spectral Mammography | A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position. |
Timeline
- Start date
- 2019-04-23
- Primary completion
- 2023-01-19
- Completion
- 2023-01-19
- First posted
- 2019-04-29
- Last updated
- 2023-01-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03929822. Inclusion in this directory is not an endorsement.